drugset / Trial / NCT00907400

Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E

NCT00907400

Phase 1 Completed 48 enrolled AstraZeneca
RandomizedCrossoverOpen-label

Summary

The purpose of the study is to investigate the uptake in the body of naproxen; one of the two active substances in PN400. We also want to show that the body's uptake of naproxen given as PN400 is comparable to that of currently marketed naproxen tablets.

Timeline

Start
2009-05
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule Oral
Subject PN400 Unknown Oral

Indications

No indication recorded.